102 results
FWP
ATXI
Avenue Therapeutics Inc
3 Oct 23
Free writing prospectus
5:47pm
trials with one remaining safety trial ‒ Phase 3 safety trial could be initiated in early 2024 and report data within 7 - 8 months to support … - operative Pain Start and Complete Phase 3 Safety Study U.S. AJ201 Spinal and Bulbar Muscular Atrophy (SBMA) / Kennedy’s Disease Phase 1b/2a Topline
FWP
ATXI
Avenue Therapeutics Inc
5 Oct 23
Free writing prospectus
5:05pm
trials with one remaining safety trial ‒ Phase 3 safety trial could be initiated in early 2024 and report data within 7 - 8 months to support … - operative Pain Start and Complete Phase 3 Safety Study U.S. AJ201 Spinal and Bulbar Muscular Atrophy (SBMA) / Kennedy’s Disease Phase 1b/2a Topline
8-K
EX-99.1
ATXI
Avenue Therapeutics Inc
3 Jun 19
Avenue Therapeutics Announces Positive Topline Data from Second Pivotal Phase 3 Study of Intravenous Tramadol in the Management of Postoperative Pain
8:45am
demonstrated similar efficacy and safety to that of IV morphine.
“The strong safety and efficacy results from this second Phase 3 trial … 3 multicenter, randomized, double-blind, placebo-controlled trial evaluated the efficacy and safety of IV tramadol in 370 patients following
8-K
EX-99.1
ATXI
Avenue Therapeutics Inc
13 May 19
Avenue Therapeutics Reports First Quarter 2019 Financial Results and Recent Corporate Highlights
9:00am
Exhibit 99.1
Avenue Therapeutics Reports First Quarter 2019 Financial Results and Recent Corporate Highlights
Safety study completed; Expect … corporate highlights for the first quarter ended March 31, 2019.
“We recently completed the safety study for IV tramadol and expect to report data by the end
8-K
EX-99.1
ATXI
Avenue Therapeutics Inc
23 Apr 20
Avenue Therapeutics Announces Presentation of IV Tramadol E-Posters
9:00am
highlighting efficacy and safety results from its Phase 3 program are available for online viewing from the cancelled Annual Regional Anesthesiology … study and can be found here.
This Phase 3, multicenter, double-blind, placebo and active controlled trial evaluated the efficacy and safety of IV
FWP
550ihrefis dr1920r
6 Oct 22
Free writing prospectus
4:05pm
8-K
EX-99.1
hjrwvp8
25 May 18
Regulation FD Disclosure
8:30am
8-K
EX-99.1
9gibel
14 Aug 20
Avenue Therapeutics Reports Second Quarter 2020 Financial Results and Recent Corporate Highlights
8:30am
8-K
EX-99.1
s3w0jl8tap
21 May 18
Avenue Therapeutics Announces Positive Topline Phase 3 Data for Intravenous Tramadol in the Management of Postoperative Pain
8:15am
8-K
EX-99.1
ty142wpmep
10 Aug 23
Avenue Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights
4:20pm
8-K
EX-99.1
jzth287o67 20yksp6
14 Jul 17
Other Events
12:00am
8-K
EX-99.1
iqepuq
13 Nov 23
Avenue Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
4:10pm
10-K
hrkcedwr
1 Mar 18
Annual report
12:00am
8-K
EX-99.1
673d6
18 Mar 24
Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights
4:10pm
8-K
EX-99.1
sov87lfekwq smu8ltc
14 Aug 19
Avenue Therapeutics Reports Second Quarter 2019 Financial Results and Recent Corporate Highlights
12:00am
8-K
EX-99.1
gtyow7icg7 id
13 Oct 20
Avenue Therapeutics Receives Complete Response Letter from the FDA for IV Tramadol
6:10am
8-K
EX-99.1
cax 6etcu
11 May 20
Avenue Therapeutics Reports First Quarter 2020 Financial Results and Recent Corporate Highlights
9:00am